APAC IPOs & Placements, Aequitas Research

Clarence Chu

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Beijing UBOX Online Technology / Equity Capital Markets

Beijing UBOX Online Technology (1741985D CH)

<ul>
<li>
<a href="https://www.smartkarma.com/entities/beijing-ubox-online-technology" target="_blank" data-smartkarma-citation="entities:36144:1" rel="noopener">Beijing UBOX Online Technology (1741985D CH)</a> is looking to raise up to US$500m in its upcoming Hong Kong IPO. </li>
<li>Beijing UBOX Online Technology (UBOX) is an unmanned retail operator (vending machine) in China. </li>
<li>As per F&amp;S, it was the largest unmanned retail operator in China, with the largest retail machine network in the country. </li>
</ul>



Beijing UBOX Online Technology (1741985D CH) is looking to raise up to US$500m in its upcoming Hong Kong IPO. 
Beijing UBOX Online Technology (UBOX) is an unmanned retail operator (vending machine) in China. 
As per F&amp;S, it was the largest unmanned retail operator in China, with the largest retail machine network in the country. 


Beijing UBOX Online Technology Pre-IPO - Trimming Losses, but yet to Factor in 2022 Lockdowns

<ul>
<li>
<a href="https://www.smartkarma.com/entities/deewin-tianxia" target="_blank" data-smartkarma-citation="entities:36075:1" rel="noopener">Deewin Tianxia (2418 HK)</a> raised around US$123m in its Hong Kong IPO.</li>
<li>DT’s subscription rates had been lackluster with weak coverage on the institutional tranche and the retail portion being undersubscribed.</li>
<li>Given its smaller size, in our view, the firm should come in at a discount to its peer average.</li>
</ul>



Deewin Tianxia (2418 HK) raised around US$123m in its Hong Kong IPO.
DT’s subscription rates had been lackluster with weak coverage on the institutional tranche and the retail portion being undersubscribed.
Given its smaller size, in our view, the firm should come in at a discount to its peer average.


Deewin Tianxia IPO Trading - Weak Subscription Rates, Retail Portion Undersubscribed

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

<ul>
<li>Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.</li>
<li>Tianqi managed to pull off the largest HK IPO so far this year, a good listing could see a pickup in other large deals.</li>
<li>For placements, SK IE couldn't hold on to its deal price, while Ming Yang kicked off what might be a busy GDR season.</li>
</ul>


Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.
Tianqi managed to pull off the largest HK IPO so far this year, a good listing could see a pickup in other large deals.
For placements, SK IE couldn't hold on to its deal price, while Ming Yang kicked off what might be a busy GDR season.


ECM Weekly (10th Jul 2022) -Tianqi, Thai Life, TPG, SK IE, Weilong, Emperador, Soosan, SoCar, Deewin

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>Microport NeuroTech is a leading neuro-interventional device company in China. The company launched a downsized deal to  raise up to USD 43m via a Hong Kong listing.</li>
<li>In our previous note, we looked at the company's key segments and products. We like the company's comprehensive coverage of neuro-interventional devices. Its management team has decent experience.</li>
<li>In this note, we provide an update for the book building. We provide our quick thoughts on the valuation and deal dynamics.</li>
</ul>


Microport NeuroTech is a leading neuro-interventional device company in China. The company launched a downsized deal to  raise up to USD 43m via a Hong Kong listing.
In our previous note, we looked at the company's key segments and products. We like the company's comprehensive coverage of neuro-interventional devices. Its management team has decent experience.
In this note, we provide an update for the book building. We provide our quick thoughts on the valuation and deal dynamics.


Microport NeuroTech (微创脑科学) IPO: Aggressive Valuation

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Bottom-Up

<ul>
<li>Due to the centralized procurement in PRC market and decreasing volume of operations in overseas markets during pandemic, <a href="https://www.smartkarma.com/entities/microport-scientific-corp" target="_blank" data-smartkarma-citation="entities:4487:1" rel="noopener">Microport Scientific (853 HK)</a>’s 2021 performance missed expectations. </li>
<li>Even if Microport could finally digest the negative impact of centralized procurement, its “unique” development mode would still put pressure and uncertainties on future performance/outlook, leading to lower-than-expected results.</li>
<li>Our earnings estimate of Microport in 2022 could be about HK$-1.7, and revenue estimate could be about HK$7.3 billion. It’s quite possible that the Company will not end up profitable.</li>
</ul>


Due to the centralized procurement in PRC market and decreasing volume of operations in overseas markets during pandemic, Microport Scientific (853 HK)’s 2021 performance missed expectations. 
Even if Microport could finally digest the negative impact of centralized procurement, its “unique” development mode would still put pressure and uncertainties on future performance/outlook, leading to lower-than-expected results.
Our earnings estimate of Microport in 2022 could be about HK$-1.7, and revenue estimate could be about HK$7.3 billion. It’s quite possible that the Company will not end up profitable.


Microport Scientific (853.HK)-The “unique” Development Mode Leads to Lower-Than-Expected Performance

China

MicroPort NeuroScientific is engaged in the research, development, and manufacturing of neuro-interventional medical devices. The company's products address three key areas of cerebrovascular disease: hemorrhagic stroke, cerebral atherosclerotic stenosis, and acute ischemic stroke. Key products include the NUMEN coil, Tubridge flow-diverting stent, and APOLLO intracranial stent. Headquartered in Shanghai, China, the company was founded in 2012.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

MicroPort NeuroScientific (2172 HK)

Beijing UBOX Online Technology Pre-IPO - Trimming Losses, but yet to Factor in 2022 Lockdowns

Beijing UBOX Online Technology (1741985D CH) is looking to raise up to US$500m in its upcoming Hong Kong IPO. UBOX is an unmanned retail operator...

Clarence Chu

Deewin Tianxia IPO Trading - Weak Subscription Rates, Retail Portion Undersubscribed

Deewin Tianxia (2418 HK) raised around US$123m in its Hong Kong IPO. DT’s subscription rates had been lackluster with weak coverage on the...

Clarence Chu

ECM Weekly (10th Jul 2022) -Tianqi, Thai Life, TPG, SK IE, Weilong, Emperador, Soosan, SoCar, Deewin

Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.

Sumeet Singh

Microport NeuroTech (微创脑科学) IPO: Aggressive Valuation

We provide a quick update for Microport Neurotech's book building. We discussed the valuation and deal dynamics. We think the valuation is rich but...

Ke Yan, CFA, FRM

Microport Scientific (853.HK)-The “unique” Development Mode Leads to Lower-Than-Expected Performance

Microport’s 2021 performance missed expectations due to VBP and pandemic. Its “unique” development mode will lead to lower-than...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)